NouvNeu001 is a cell replacement therapy for Parkinson's disease (PD) that uses human dopaminergic progenitor cells derived from stem cells. The therapy aims to restore dopamine production in the brains of patients with mid- to late-stage Parkinson's disease by transplanting dopaminergic neurons that can integrate into the existing neural circuitry and produce dopamine.
| Parameter |
Value |
| NCT Number |
NCT06167681 |
| Status |
Recruiting |
| Phase |
Phase I/II |
| Sponsor |
iRegene Therapeutics Co., Ltd. |
| Intervention |
NouvNeu001 (human dopaminergic progenitor cells) |
| Route |
Intracerebral injection |
| Enrollment |
40 participants (estimated) |
| Start Date |
January 17, 2024 |
| Completion Date |
July 2029 |
| Locations |
Beijing, China; Wuhan, China |
NouvNeu001 represents a cell replacement therapy approach that addresses the core pathological feature of Parkinson's disease — the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.
- Dopaminergic Progenitor Cells — NouvNeu001 consists of human dopaminergic progenitor cells that are programmed to develop into mature dopamine-producing neurons
- Cell Transplantation — Cells are injected directly into the brain regions affected by dopamine loss (typically the striatum or substantia nigra)
- Neuronal Integration — The transplanted cells can potentially:
- Extend axons to target regions
- Form functional synaptic connections
- Integrate into existing neural circuits
- Dopamine Production — Mature dopaminergic neurons produce and release dopamine, restoring the neurotransmitter deficiency that causes motor symptoms
The loss of dopaminergic neurons in Parkinson's disease leads to:
- Reduced dopamine signaling in the striatum
- Motor symptoms (tremor, bradykinesia, rigidity)
- Eventually, non-motor symptoms (cognitive decline, autonomic dysfunction)
While current treatments like levodopa (a dopamine precursor) and deep brain stimulation manage symptoms, they do not address the underlying neuronal loss. Cell replacement therapy aims to:
- Replace lost neurons
- Potentially restore normal dopamine regulation
- Slow or halt disease progression
- Improve long-term outcomes
- Source: Derived from human embryonic stem cells
- Advantages: Unlimited proliferative capacity, can be directed to become dopaminergic neurons
- Challenges: Risk of tumor formation (teratomas), ethical concerns, immune rejection
- Examples: Previous trials using fetal tissue (historical), ESC-derived approaches
- Source: Patient's own cells reprogrammed to pluripotent state, then differentiated
- Advantages: Autologous (patient's own cells), reduced immune rejection, personalized therapy
- Challenges: Expensive, time-consuming (6-12 months to produce cells), variable quality
- Current Status: Several clinical trials in Japan and other countries
| Feature |
ESC |
iPSC |
NouvNeu001 |
| Source |
Embryonic stem cells |
Patient's own cells |
Allogeneic (donor-derived) |
| Immune Rejection |
Requires immunosuppression |
Minimal (autologous) |
Requires immunosuppression |
| Production Time |
Weeks |
Months |
Off-the-shelf possible |
| Cost |
Moderate |
High |
Potentially lower at scale |
| Tumor Risk |
Yes |
Lower |
Being evaluated |
- Allogeneic (Off-the-Shelf) — Can be produced in bulk and stored, allowing for immediate treatment when needed
- Standardized Manufacturing — Consistent product quality through GMP production
- Reduced Patient Burden — No need for extended cell culture period (unlike iPSC approaches)
- Established Safety Profile — Being evaluated in Phase I/II trials
Cell replacement therapy for PD has a long history, with preclinical and clinical evidence supporting the approach:
- Non-human primate studies: Demonstrated that transplanted dopaminergic neurons can survive, integrate, and improve motor function in parkinsonian primates
- Rodent studies: Showed proof of concept for dopamine production and functional recovery
- Fetal tissue transplants (1980s-1990s): Showed some patients experienced significant improvement, but results were variable and the approach was discontinued due to ethical concerns and inconsistent outcomes
- Modern cell therapy: Newer approaches using ESC and iPSC derivatives have shown promise in early-phase clinical trials
Primary Objectives:
- Assess safety and tolerability of NouvNeu001 injection
- Evaluate efficacy through motor function assessments
Key Endpoints:
- Adverse events (safety monitoring)
- Motor function improvement (UPDRS scores)
- Quality of life measures
Inclusion Criteria (typical for PD cell therapy trials):
- Diagnosis of idiopathic Parkinson's disease
- Mid- to late-stage disease
- On/off fluctuations or inadequate response to standard therapy
- Intracranial Hemorrhage — Risk from the surgical procedure of cell injection
- Infection — Any brain surgery carries infection risk
- Immunological Rejection — Allogeneic cells may be recognized as foreign
- Dyskinesias — Abnormal involuntary movements, observed in some historical transplant trials
- Tumor Formation — Theoretical risk with any cell therapy, though considered low with progenitor cells
- Graft Failure — Cells may not survive or integrate properly
- Careful surgical technique
- Immunosuppressive therapy as needed
- Rigorous cell characterization and quality control
- Close monitoring during follow-up
NouvNeu001 represents an important step in the development of disease-modifying therapies for Parkinson's disease:
- Addresses Root Cause — Unlike symptomatic treatments, cell replacement aims to replace lost neurons
- Potential for Long-Term Benefit — Single treatment could provide years of benefit
- Advances Cell Therapy Field — Contributes to understanding of optimal cell delivery and integration
| Therapy Type |
Approach |
Disease-Modifying Potential |
| Levodopa/Dopamine Agonists |
Symptomatic relief |
None |
| Deep Brain Stimulation |
Electrical modulation |
None |
| GDNF/Neurturin |
Protein delivery |
Potential |
| Alpha-Synuclein Therapies |
Target aggregation |
Potential |
| Cell Replacement (NouvNeu001) |
Replace neurons |
High potential |